68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers
暂无分享,去创建一个
Frederik L. Giesel | Thomas Lindner | Wencke Lehnert | Uwe Haberkorn | Jürgen Debus | Annette Altmann | Walter Mier | Dirk Jäger | D. Jäger | U. Haberkorn | J. Debus | F. Giesel | C. Kratochwil | A. Altmann | W. Mier | P. Flechsig | W. Lehnert | Clemens Kratochwil | T. Lindner | Anastasia Loktev | Manfred M. Marschalek | Paul Flechsig | A. Loktev
[1] K. F. Eckerman,et al. Specific absorbed fractions of energy at various ages from internal photon sources: 6, Newborn , 1987 .
[2] K. F. Eckerman,et al. Specific absorbed fractions of energy at various ages from internal photon sources: 2, One-year-old , 1987 .
[3] S. Mattsson,et al. Effective dose from radiopharmaceuticals , 2004, European Journal of Nuclear Medicine.
[4] Michael G Stabin,et al. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] Mijin Yun,et al. The Importance of Acetyl Coenzyme A Synthetase for 11C-Acetate Uptake and Cell Survival in Hepatocellular Carcinoma , 2009, Journal of Nuclear Medicine.
[6] Paul DeLuca,et al. Realistic reference phantoms: An ICRP/ICRU joint effort , 2009, Annals of the ICRP.
[7] Carlo Chiesa,et al. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[8] M. Büchler,et al. Pancreatic cancer: FDG-PET is not useful in early pancreatic cancer diagnosis , 2013, Nature Reviews Gastroenterology &Hepatology.
[9] Anders Sundin,et al. Comparative Biodistribution and Radiation Dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in Patients with Neuroendocrine Tumors , 2013, The Journal of Nuclear Medicine.
[10] H. Janssen,et al. Increased N‐terminal cleavage of alpha‐2‐antiplasmin in patients with liver cirrhosis , 2013, Journal of thrombosis and haemostasis : JTH.
[11] A. Lambeir,et al. Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold. , 2013, ACS medicinal chemistry letters.
[12] J. Lai,et al. Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. , 2013, Journal of medicinal chemistry.
[13] O. Schilling,et al. Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy , 2014, Proteomics. Clinical applications.
[14] P. Galuppo,et al. Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. , 2015, Journal of molecular and cellular cardiology.
[15] N Petoussi-Henss,et al. ICRP Publication 133: The ICRP computational framework for internal dose assessment for reference adults: specific absorbed fractions , 2016, Annals of the ICRP.
[16] M. Schwaiger,et al. Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CC—a PSMA specific probe for PET imaging of prostate cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[17] U. Haberkorn,et al. Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[18] C Cousins,et al. The future of ICRP: towards a centenary and beyond , 2016, Annals of the ICRP.
[19] Christine Egger,et al. Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis , 2017, European journal of pharmacology.
[20] J. Berlin,et al. Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.
[21] Sören Mattsson,et al. IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms , 2017, EJNMMI Research.
[22] D. Murphy,et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. , 2018, The Lancet. Oncology.
[23] Thomas Lindner,et al. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein , 2018, The Journal of Nuclear Medicine.
[24] D. Jäger,et al. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts , 2018, The Journal of Nuclear Medicine.